ZVIA vs. REED, KOF, FMX, MNST, CCEP, CELH, COKE, FIZZ, PRMW, and CADL
Should you be buying Zevia PBC stock or one of its competitors? The main competitors of Zevia PBC include Reed's (REED), Coca-Cola FEMSA (KOF), Fomento Económico Mexicano (FMX), Monster Beverage (MNST), Coca-Cola Europacific Partners (CCEP), Celsius (CELH), Coca-Cola Consolidated (COKE), National Beverage (FIZZ), Primo Water (PRMW), and Candel Therapeutics (CADL).
Zevia PBC (NYSE:ZVIA) and Reed's (NYSE:REED) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.
Reed's has lower revenue, but higher earnings than Zevia PBC. Zevia PBC is trading at a lower price-to-earnings ratio than Reed's, indicating that it is currently the more affordable of the two stocks.
Zevia PBC received 14 more outperform votes than Reed's when rated by MarketBeat users. Likewise, 31.91% of users gave Zevia PBC an outperform vote while only 1.54% of users gave Reed's an outperform vote.
In the previous week, Reed's had 3 more articles in the media than Zevia PBC. MarketBeat recorded 4 mentions for Reed's and 1 mentions for Zevia PBC. Zevia PBC's average media sentiment score of 0.14 beat Reed's' score of 0.00 indicating that Zevia PBC is being referred to more favorably in the media.
Zevia PBC has a net margin of -15.58% compared to Reed's' net margin of -29.75%. Reed's' return on equity of 0.00% beat Zevia PBC's return on equity.
Zevia PBC currently has a consensus price target of $3.21, suggesting a potential upside of 276.70%. Reed's has a consensus price target of $7.00, suggesting a potential upside of 338.87%. Given Reed's' stronger consensus rating and higher probable upside, analysts clearly believe Reed's is more favorable than Zevia PBC.
53.2% of Zevia PBC shares are owned by institutional investors. Comparatively, 51.5% of Reed's shares are owned by institutional investors. 12.6% of Zevia PBC shares are owned by insiders. Comparatively, 46.7% of Reed's shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Zevia PBC has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, Reed's has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.
Summary
Zevia PBC beats Reed's on 10 of the 18 factors compared between the two stocks.
Get Zevia PBC News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZVIA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZVIA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zevia PBC Competitors List
Related Companies and Tools
